Pulmonx Executives to Attend Two November Conferences
Management will participate in back-to-back healthcare investment forums on November 11, 2026.
Updated on Oct. 28, 2026 in Asthma
Pulmonx Corporation leadership will engage in investor discussions at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the Stifel 2026 Healthcare Conference on November 11, 2026. These appearances will feature fireside chats and private meetings regarding the company's work in severe lung disease treatment.
Why it matters
These appearances provide a platform for company leaders to engage with the investment community regarding their proprietary medical device portfolio. Engaging with analysts and stakeholders at these forums helps provide visibility into the company's progress within the specialized lung health sector.
The Zephyr Valve, which holds FDA Premarket Approval, is currently available for patients in more than 25 countries. The Canaccord Genuity forum session is scheduled for 9:30 AM ET, followed by the Stifel conference session at 10:40 AM ET.
The players
Pulmonx Corporation
A developer of medical treatments and diagnostic tools for patients suffering from severe lung diseases.
The details
Redwood City-based Pulmonx Corporation develops technologies such as the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX Platform. Management plans to use these sessions to conduct one-on-one meetings alongside their scheduled fireside chats.
Timeline
November 11, 2026: Canaccord Genuity Forum fireside chat from 9:30 AM to 9:55 AM ET.
November 11, 2026: Stifel 2026 Healthcare Conference fireside chat from 10:40 AM to 11:10 AM ET.
Health Landscape
The company leverages devices that have successfully cleared the FDA Premarket Approval process to secure a competitive foothold in the respiratory care market. These appearances align with industry norms for firms managing high-tech medical portfolios to update institutional investors on global growth.
These investor events do not change daily treatment options or medical routines for patients using company devices. Patients currently receiving care should continue to rely on their healthcare providers for information regarding their specific medical regimens.
The takeaway
Investor conferences serve as a primary venue for medical device companies to disclose strategic shifts to the financial community. Stakeholders often use these sessions to gauge the company's long-term product roadmap and market expansion efforts.
Further reading
Learn more about the latest innovations and developments in the field by visiting the Asthma section.
More information
View upcoming webcasts and investor materials on the Pulmonx investor relations webcasts portal.
Source note: This article includes information reported by The Manila times.
